Lilly reported Q3 2026 revenue of $24.4 billion, a 39% increase, driven by Mounjaro and Zepbound, and raised its full-year 2026 revenue guidance to $91.0 to $92.0 billion.
Lilly reported Q3 2026 revenue of $24.4 billion, a 39% increase, driven by Mounjaro and Zepbound, and raised its full-year 2026 revenue guidance to $91.0 to $92.0 billion.